Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 DC Vaccine and DLI for Hematologic Malignancies
NCT00923910Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2008
- Primary completion
- Oct 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 peptide-pulsed dendritic cells in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML), myelodysplastic syndrome (MDS), non-Hodgkin lymphoma (NHL), sponsored by National Cancer Institute. Started Feb 2008; status: completed.
02
Drugs
WT1 peptide-pulsed dendritic cells
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)myelodysplastic syndrome (MDS)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00923910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923910.